Univariate and multivariate analyses for NRM
| Characteristics . | Univariate analysis . | Multivariate analysis . | |
|---|---|---|---|
| P value . | HR (95% CI) . | P value . | |
| Letermovir prophylaxis | .24 | 0.743 (0.556-0.993) | .045 |
| Patient age at HSCT, >50 y | <.001 | 1.56 (1.30-1.87) | <.001 |
| AML | .88 | ||
| ALL | <.001 | 0.996 (0.786-1.26) | .97 |
| AA | .002 | 0.613 (0.286-1.32) | .21 |
| CML | .072 | ||
| MDS | .087 | ||
| Disease risk high | <.001 | 1.93 (1.61-2.32) | <.001 |
| PS > 1 | <.001 | 1.84 (1.46-2.32) | <.001 |
| HCT-CI > 2 | <.001 | 1.28 (1.06-1.53) | <.001 |
| Donor CMV IgG | .58 | ||
| HLA-matched BMT | <.001 | 0.768 (0.592-0.998) | .048 |
| HLA-matched PBSCT | .008 | 0.776 (0.576-1.05) | .095 |
| HLA-mismatched BMT | .24 | ||
| HLA-mismatched PBSCT | <.001 | 1.11 (0.856-1.45) | .42 |
| CBT | <.001 | 1.19 (0.942-1.49) | .15 |
| Female donor to male recipient | .053 | ||
| Unrelated donor | .15 | ||
| Number of HSCT > 1 | <.001 | 1.84 (1.51-2.26) | <.001 |
| MAC | <.001 | 1.16 (0.970-1.40) | .10 |
| ATG use | .003 | 1.14 (0.902-1.45) | .27 |
| Characteristics . | Univariate analysis . | Multivariate analysis . | |
|---|---|---|---|
| P value . | HR (95% CI) . | P value . | |
| Letermovir prophylaxis | .24 | 0.743 (0.556-0.993) | .045 |
| Patient age at HSCT, >50 y | <.001 | 1.56 (1.30-1.87) | <.001 |
| AML | .88 | ||
| ALL | <.001 | 0.996 (0.786-1.26) | .97 |
| AA | .002 | 0.613 (0.286-1.32) | .21 |
| CML | .072 | ||
| MDS | .087 | ||
| Disease risk high | <.001 | 1.93 (1.61-2.32) | <.001 |
| PS > 1 | <.001 | 1.84 (1.46-2.32) | <.001 |
| HCT-CI > 2 | <.001 | 1.28 (1.06-1.53) | <.001 |
| Donor CMV IgG | .58 | ||
| HLA-matched BMT | <.001 | 0.768 (0.592-0.998) | .048 |
| HLA-matched PBSCT | .008 | 0.776 (0.576-1.05) | .095 |
| HLA-mismatched BMT | .24 | ||
| HLA-mismatched PBSCT | <.001 | 1.11 (0.856-1.45) | .42 |
| CBT | <.001 | 1.19 (0.942-1.49) | .15 |
| Female donor to male recipient | .053 | ||
| Unrelated donor | .15 | ||
| Number of HSCT > 1 | <.001 | 1.84 (1.51-2.26) | <.001 |
| MAC | <.001 | 1.16 (0.970-1.40) | .10 |
| ATG use | .003 | 1.14 (0.902-1.45) | .27 |
AA, aplastic anemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BMT, bone marrow transplantation; CBT, cord blood transplantation; CML, chronic myeloid leukemia; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MAC, myeloablative conditioning; MDS, myelodysplastic syndromes; PBSCT, peripheral blood stem cell transplantation.